These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 36094679)

  • 1. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Skeeters SS; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    EMBO Mol Med; 2022 Nov; 14(11):e16109. PubMed ID: 36094679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    bioRxiv; 2022 Mar; ():. PubMed ID: 35378764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
    Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
    Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
    Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
    Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
    Zhang H; Hu B; Lv P; Liu Y; Guo M; Wu Z; Zhou K; Dai M; Yu X; Liu Z; Yu B; Xu L; Guo M; Cai K; Li Y
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
    Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
    Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
    Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A
    Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2.
    Wang R; Zhang Q; Zhang R; Aw ZQ; Chen P; Wong YH; Hong J; Ju B; Shi X; Ding Q; Zhang Z; Chu JJH; Zhang L
    Front Immunol; 2022; 13():854952. PubMed ID: 35784344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
    Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
    Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development.
    Zhang Z; Zhou L; Liu Q; Zheng Y; Tan X; Huang Z; Guo M; Wang X; Chen X; Liang S; Li W; Song K; Yan K; Li J; Li Q; Zhang Y; Yang S; Cai Z; Dai M; Xian Q; Shi ZL; Xu K; Lan K; Chen Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2353302. PubMed ID: 38753462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1.
    Li L; Liao H; Meng Y; Li W; Han P; Liu K; Wang Q; Li D; Zhang Y; Wang L; Fan Z; Zhang Y; Wang Q; Zhao X; Sun Y; Huang N; Qi J; Gao GF
    Cell; 2022 Aug; 185(16):2952-2960.e10. PubMed ID: 35809570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors.
    Weidenbacher PA; Waltari E; de Los Rios Kobara I; Bell BN; Morris MK; Cheng YC; Hanson C; Pak JE; Kim PS
    Nat Chem Biol; 2022 Nov; 18(11):1270-1276. PubMed ID: 36076082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    Kumar S; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.